Recent Finacing
Recent Raise
Aragon Pharmaceuticals develops small-molecule anti-hormonal therapeutics for hormone-driven cancers, advancing ARN-509 (androgen receptor antagonist) in Phase II for castration-resistant prostate cancer and a SERD for ER+ breast cancer.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
